Site Loader

not generalizable to other RCTs. Goal Attainment Scaling (GAS); Global Measures. Clinician Interview-Based Impression of Change plus caregiver input ( CIBIC. interview [CIBIC-plus]). The ADAS- cog, disease assessment in dementia scale, and neuropsychiatric inventory are recorded by supervising site investigator, but . The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC -Plus), is widely used in antidementia drug trials. It comprises Likert scales for.

Author: Molmaran Tygora
Country: Nigeria
Language: English (Spanish)
Genre: Video
Published (Last): 26 May 2008
Pages: 482
PDF File Size: 7.16 Mb
ePub File Size: 2.85 Mb
ISBN: 936-9-94440-314-3
Downloads: 96342
Price: Free* [*Free Regsitration Required]
Uploader: Vusida

Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http: Allergy and Immunology The central raters consisted of eight AD experts. Obstetrics and Gynecology Dement Geriatr Cogn Disord 4;24 2: Epub Jul To evaluate efficacy and safety of galantamine for cibci with vascular dementia VaD.

We addressed how the increased use of the nursing-care services might affect the information scwle the patients provided by their caregivers.

The global severity scales are clearly useful in subject categorization in treatment trials, in part because they are relatively free of many of the sociocultural biases inherent in mental status and psychometric descriptors.

The sites where this method can be conducted are limited, because a sufficiently large room must be available for the videotaping, as well as sufficient time for the videotaping process. Donepezil is an established treatment for mild, moderate, and severe Alzheimer’s disease AD.

Variability of CIBIC plus-J arises among raters in accordance with their experience and their memories of patients’ conditions at baseline. Here, we present the method and results. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability or efficacy.


CIBIC-plus Publications | PubFacts

Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer’s disease AD. A Meta-analysis of 14 Randomized Trials. Measurement of observer agreement. ICC in the present study was 0. Trials 06 8;17 1: J Clin Psychopharmacol Aug;29 4: However, CIBIC plus-J is generally conducted at clinical sites, and we consider that greater variability would arise among raters at such sites in accordance with their experience.

Clinical Development Eisai Co. A week, randomized, parallel-group, double-blind placebo-controlled study was conducted to evaluate the efficacy and tolerability of donepezil in severe Alzheimer’s disease AD.

Epub Jun 5.

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

Cochrane Database Syst Rev Apr 16 2: A new rating scale for Alzheimer’s disease. Murata, Azumi General Hospital. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: As a result, the kappa coefficient showed a moderate agreement of 0.

Acknowledgements We would like to thank the following principal investigators and their staffs for patient recruiting, interviews and video-recording: Evid Based Complement Alternat Med 26; Epub Aug Neurology Nov;71 Latrepirdine may modulate several targets involved in AD pathology, including lipid peroxidation, mitochondrial permeability, voltage-gated calcium ion channels as well as neurotransmitter receptor activity, and thus potentially represents both a symptomatic and disease-modifying intervention.

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

This would give rise to a high placebo effect in the evaluation of drug efficacy. Evidence from six-month randomized trials and long-term observational studies supports superiority of memantine-ChEI combination to ChEI monotherapy. National Center for Biotechnology InformationU. The aim of the present report was to examine the reliabilities of the subscale items and investigate their relationships with CGIC. However, given the relative scarcity of effective treatments for AD it would seem prudent to re-examine existing evidence to determine whether or not memantine should be used.


The efficacy and safety of Fufangdanshen tablets Radix Salviae miltiorrhizae formula tablets for mild to moderate vascular dementia: Author information Copyright and License information Disclaimer.

Dement Geriatr Cogn Disord 28;23 2: Acupuncture has attracted more and more attention in recent years due to its efficacy and very few side effects. Anticholinergic challenge can induce odor identification impairment that indicates Alzheimer’s disease pathology. Physical Medicine and Rehabilitation Ann Neurol Jul;72 1: Vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease hereinafter, subcortical Vascular cognitive impairment without dementia represents a relatively homogeneous scald process and is a suitable target for therapeutic trials investigating Vascular scalr impairment without dementia.

Combination therapy for patients with Alzheimer disease AD was suggested, but the additional benefit of combination therapy is still controversial.

The entorhinal cortex and the olfactory bulb, critical areas for olfactory function, scle rich in acetylcholine, the neurotransmitter implicated in AD pathology and treatment.

Disclosure Statement This report is based on the data of a clinical trial that was sponsored by Dainippon Sumitomo Pharma Co.

Search Our Scientific Publications & Authors

Olfactory dysfunction, impaired odor identification in particular, is known to occur in Alzheimer disease AD. Efficacy was evaluated using measures of cognition, daily function, and behavior. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: Development of a functional measure for persons with Alzheimer’s disease: Memantine treatment in patients with mild to moderate Alzheimer’s disease: Published online Jul